𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vivo tumor angiogenesis imaging with site-specific labeled99mTc-HYNIC-VEGF

✍ Scribed by Francis G. Blankenberg; Marina V. Backer; Zoia Levashova; Vimalkumar Patel; Joseph M. Backer


Publisher
Springer
Year
2006
Tongue
English
Weight
256 KB
Volume
33
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


In vivo labelling of RBC with99mTc for b
✍ H. I. Popescu; J. Lessem; M. Erjavec; G. F. FΓΌger πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 498 KB

The in vivo 99mTc-RBC labelling efficiency and stability of labelling was assessed after pretinning with a high-stannous content DTPA kit (Sn DTPA) in comparison with Sn-pyrophosphate (Sn PPi) and a low-stannous DTPA kit (DTPA). The distribution in Sprague Dawley rats showed that similar fractions o

An improved method for the in vivo label
✍ Coskun F. Bekdik; Meral T. Ercan; Irem Bernay; Biray E. Caner; Sevinc Turguter πŸ“‚ Article πŸ“… 1988 πŸ› Springer 🌐 English βš– 510 KB

Red blood cells of 10 patients were labelled with 99mTc by the in vivo method, 5 of the patients were orally administered with 400 mg potassium perchlorate at the time of stannous pyrophosphate injection and 5 ml blood was withdrawn at 10 min postinjection of pertechnetate to determine the labelling

PET imaging of tumor angiogenesis in mic
✍ Tapan K. Nayak; Kayhan Garmestani; Kwamena E. Baidoo; Diane E. Milenic; Martin W πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 407 KB

## Abstract Bevacizumab is a humanized monoclonal antibody that binds to tumor‐secreted vascular endothelial growth factor (VEGF)‐A and inhibits tumor angiogenesis. In 2004, the antibody was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal carcinoma i